Group 1 - The ChiNext index showed strong performance, rising over 1% with active participation from innovative drug and commercial aerospace concepts [1][2][3] - The ChiNext index rose by 1.36% at midday, with notable stocks such as Lens Technology (300433) increasing over 8% and Ningde Times (300750) nearly 4% [2][3] - The innovative drug concept saw significant gains, with multiple stocks hitting the daily limit, including ShenZhou Cell and Jiuzhitang [3][6] Group 2 - The Hong Kong stock market experienced a slight decline, with the Hang Seng Index dropping over 1% at one point [9] - Multi-point Intelligence saw its stock price surge, with an intraday increase nearing 90%, attributed to its plans for a stablecoin license [10][12] - The pharmaceutical sector in the Hong Kong market rose over 2%, with several stocks, including Huahao Zhongtian Pharmaceutical-B, increasing over 10% [12] Group 3 - JiXin Technology (601218) experienced its fourth consecutive trading day of hitting the daily limit, while issuing a risk warning regarding its high rolling P/E ratio of 72.85 compared to the industry average of 22.24 [7][8] - SaiLi Medical also hit the daily limit for the third consecutive day, with the company confirming no undisclosed significant information affecting its stock price [8]

Core Viewpoint - The hepatitis concept sector has seen a 2.30% increase, ranking 10th among concept sectors, with significant gains from stocks like Guizhou Bailing, Weiming Pharmaceutical, and Kexing Pharmaceutical [1]. Group 1: Sector Performance - The hepatitis concept sector had 116 stocks rising, with Guizhou Bailing, Weiming Pharmaceutical, and *ST Sailong hitting the daily limit up [1]. - Notable gainers included Kexing Pharmaceutical, Yipin Hong, and Rejing Biological, which rose by 15.62%, 14.72%, and 11.60% respectively [1]. - The sector's performance was contrasted by declines in stocks like *ST Suwu, *ST Sihuan, and New Industry, which fell by 0.79%, 0.78%, and 0.48% respectively [1]. Group 2: Capital Inflow - The hepatitis concept sector attracted a net inflow of 790 million yuan, with 71 stocks receiving net inflows [1]. - Yipin Hong led the net inflow with 168 million yuan, followed by Guizhou Bailing and Kexing Pharmaceutical with net inflows of 158 million yuan and 97.8 million yuan respectively [1]. - The top three stocks by net inflow rates were Guizhou Bailing at 17.80%, Weiming Pharmaceutical at 16.28%, and Kexing Pharmaceutical at 14.10% [2].

Core Viewpoint - The A-share innovative drug sector experienced a significant surge on July 1, driven by favorable policy announcements from the National Medical Insurance Administration and the National Health Commission, which aim to support the high-quality development of innovative drugs [1][4]. Group 1: Market Performance - Frontier Biotech reached a 20% limit-up, with other companies like Guizhou BaiLing, Saily Medical, and AngliKang also hitting their limits [2]. - Notable stock performances included: - Frontier Biotech: 12.05 (+20.02%) - Kexing Pharmaceutical: 44.19 (+15.62%) - Yuyuan Pharmaceutical: 22.00 (+15.55%) - Shuyitai: 43.00 (+15.34%) - Rongchang Biotech: 68.39 (+13.04%) [3]. Group 2: Policy Support - The new measures encourage the use of medical insurance data for innovative drug research and development, enhancing collaboration among medical, insurance, and pharmaceutical sectors [4][6]. - The policy promotes the expansion of commercial health insurance investments in innovative drugs, establishing a new directory for innovative drugs that exceed basic insurance coverage [6]. - The National Medical Insurance Administration plans to streamline the application process for including drugs in both commercial and medical insurance directories, reducing the administrative burden on companies [6]. Group 3: Industry Outlook - The innovative drug sector is in a golden development phase, with over 20 first-class innovative drugs approved for market entry from January to May, marking a five-year high [7]. - Chinese pharmaceutical companies are accelerating their international expansion, with over 90 overseas licensing transactions expected in 2024, totaling over $50 billion [7]. - Significant licensing deals include: - 12.5 billion USD deal by 3SBio - 53.3 billion USD collaboration between CSPC and AstraZeneca - 42.3 billion USD agreement by Rongchang Biotech [7]. - Several biotech firms are increasing R&D investments through share placements, with funds directed towards global R&D pipelines [8]. Group 4: Investment Sentiment - Analysts agree on the sustainable growth potential of the innovative drug sector, emphasizing the "innovation + internationalization" trend as a core focus for the pharmaceutical industry [9]. - Investment opportunities are seen in the upstream pharmaceutical supply chain, advanced manufacturing, and healthcare services, with a focus on companies with strong growth potential and profitability [9].

Group 1 - The company's retrial application was rejected, and it has fully accrued estimated liabilities and losses based on the second-instance judgment, which will not negatively impact the company's current or future profits [1][3]. - The court ruled that the company must compensate for half of the amount owed to Shen Xiangxin, totaling 60,960,436.85 yuan, within ten days of the judgment taking effect [3]. - As of the announcement date, the company has no other undisclosed litigation or arbitration matters [3]. Group 2 - The company emphasizes the importance of accurate and complete information disclosure, ensuring that there are no false records or misleading statements [1][4]. - The company has designated a specific media outlet for information disclosure, and all information will be published through this channel [4].

证券代码：002581 证券简称：未名医药 公告编号：2025-044 山东未名生物医药股份有限公司 1、案件所处的诉讼阶段：再审审查终结，山东未名生物医药股份有限公司 （以下简称"公司"）的再审申请被驳回 2、公司所处的当事人地位：再审申请人 3、涉及的金额：3,048.02 万元 4、对上市公司损益产生的影响：公司已根据本次诉讼事项二审判决全额计 提预计负债和损失，不会对公司本期利润及期后利润产生负面影响。 一、本次诉讼的基本情况 关于涉及诉讼事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 2024 年 2 月，自然人沈祥鑫与公司因缔约过失发生纠纷，对公司提起诉讼。 2024 年 9 月 29 日，公司收到浙江省杭州市上城区人民法院《民事判决书》（2024） 浙 0102 民初 2640 号，判决驳回沈祥鑫全部诉讼请求。应收案件受理费 224,703 元，由原告沈祥鑫负担。原告不服民事判决，向中级人民法院提起上诉。 2025 年 4 月，公司收到浙江省杭州市上城区人民法院《民事判决书》（2024） 浙 01 民终 1100 ...

证券代码：002581 证券简称：未名医药 公告编号：2025-042 山东未名生物医药股份有限公司 关于增资取得四川固康药业有限责任公司 51%股权的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 山东未名生物医药股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议、第六届董事会战略决策委员会第一次会 议，审议通过了《关于增资取得四川固康药业有限责任公司 51%股权的议案》, 同意公司全资子公司北大未名（上海）生物制药有限公司（以下简称"上海未 名"）向四川固康药业有限责任公司（以下简称"固康药业"）增资人民币 4,500 万元，取得固康药业 51%股权。交易完成后，固康药业将成为上海未名控 股子公司，纳入公司合并报表范围。 截至本公告披露之日，公司办理完成了固康药业相关工商变更登记与备案 手续，并取得了由都江堰市行政审批局换发的营业执照，现将有关事项的进展 公告如下： 1、股权变更情况： | | | 变更前 | | | | 变更后 | | | --- | --- | --- | --- | --- | ...

证券代码：002581 证券简称：未名医药 公告编号：2025-043 山东未名生物医药股份有限公司 关于控股子公司暂停生产、销售的进展及风险提示公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 重要风险提示： 1、山东未名生物医药股份有限公司（简称"公司""本公司"）控股子公司 天津未名生物医药有限公司（简称"天津未名"）于 2025 年 4 月 22 日被天津市 药品监督管理局采取暂停生产、销售风险控制措施。天津未名主要从事人干扰素 药品的生产与销售，2024 年，天津未名实现营业收入人民币 21,656.83 万元、净 利润人民币-1,400.37 万元，分别占同期本公司营业收入的 60.09%、合并报表净 利润的 9.8%，为公司重要子公司，本次暂停生产、销售事项对公司生产经营产生 重要影响。 一、暂停生产、销售概况 2025 年 4 月 22 日，天津市药品监督管理局发布《关于暂停天津未名生物医 药有限公司生产销售的公告》，天津市药品监督管理局对天津未名生物医药有限 公司进行了药品 GMP 符合性检查。经综合评定、研判，天津未名生物医药有限公 ...

Core Points - The company, Shandong Weiming Bio-Pharmaceutical Co., Ltd. (referred to as "Weiming Pharmaceutical"), is proposing a compensation plan for its directors and senior management to enhance governance and incentivize performance [1][2] - The compensation plan for directors requires approval from the shareholders' meeting to be implemented [1] - The independent directors will receive an annual allowance of RMB 100,000 (pre-tax), paid biannually [2] - Non-independent directors holding other management positions will receive compensation based on their roles and performance evaluations, without additional director allowances [2] - Senior management compensation will be determined by their positions and responsibilities, with basic salaries paid monthly and performance bonuses based on company and individual performance [2] Summary by Sections Applicable Parties - The compensation plan applies to the company's directors and senior management [1] Duration of the Plan - The director compensation plan will take effect upon approval by the shareholders' meeting, while the senior management plan will take effect after the board's approval [1] Compensation Details - Independent directors will receive a pre-tax allowance of RMB 100,000 per year, distributed biannually [2] - Non-independent directors without management roles will also receive the same allowance [2] - Senior management will receive a basic salary based on their roles, with performance-based compensation linked to company performance and individual contributions [2] Other Provisions - Reasonable expenses incurred while performing duties will be covered by the company [2] - The compensation plan must comply with national and local laws and regulations [2]

证券代码：002581 证券简称：未名医药 公告编号：2025-039 山东未名生物医药股份有限公司 关于增资取得四川固康药业有限责任公司 51%股权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、山东未名生物医药股份有限公司（以下简称"公司"）全资子公司北大 未名（上海）生物制药有限公司（以下简称"上海未名"）拟向四川固康药业有 限责任公司（以下简称"固康药业"或"标的公司"）增资人民币 4,500 万元， 取得固康药业 51%股权。 2、本次增资取得固康药业 51%的股权不构成关联交易，也不构成《上市公司 重大资产重组管理办法》规定的重大资产重组。 3、本次交易已经公司第六届董事会第二次会议审议通过，根据《深圳证券 交易所股票上市规则》相关规定，本次交易可免于提交股东大会审议。 一、交易概述 二、增资标的基本情况 1、公司名称：四川固康药业有限责任公司 2、统一社会信用代码：91510181057490557M 3、注册资本:2,000 万元 4、成立日期：2012 年 11 月 27 日 5、法定代表人：韩学贞 6、地址：四川省 ...

证券代码：002581 证券简称：未名医药 公告编号：2025-040 本公司董事及高级管理人员 二、适用期限 董事薪酬方案自公司股东会审议通过后生效，至新的薪酬方案通过之日 止，高级管理人员薪酬方案自本次董事会审议通过后生效，至新的薪酬方案通 过之日止。 三、薪酬方案 1、董事薪酬方案 山东未名生物医药股份有限公司 关于董事、高级管理人员薪酬方案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 山东未名生物医药股份有限公司（以下简称"未名医药"）于 2025 年 6 月 23 日召开第六届董事会第二次会议，审议了《关于第六届董事薪酬方案的议 案》《关于公司高级管理人员薪酬方案的议案》，为激励公司的董事、高级管 理人员忠实、勤勉地履行岗位职责，完善公司治理结构和激励约束机制，实现 公司持续、稳定、健康地发展，根据《公司章程》有关规定，参考行业及地区 的收入水平，并结合公司的实际情况，制定公司董事、高级管理人员薪酬方 案，《关于第六届董事薪酬方案的议案》尚需提交公司股东会审议通过方可实 施。具体情况如下： 一、适用对象 2、公司董事、高级管理人员出席或列 ...